Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

APACHE II system, is a simple and inexpensive method to evaluate severity of Intensive Care Patients. In a 2 years period (between 1988 and 1990), grading severity using APACHE II system, was performed on 498 consecutive mechanical Ventilated Patients in a Respiratory Intensive Care Unit. APACHE II was higher in COPD patients, but patients with Pneumonia and Organophosphate Poisoning had higher mortality. Correlating the different components of APACHE II with the results, we verified that Prognosis was not influenced by the Previous Health Status. Mortality was higher with increasing age, in patients with COPD and Organophosphate Poisoning. APS was the most important index for prognosis. Patients with Pneumonia and Organophosphate Poisoning had the highest APS. The Authors conclude that APACHE II is an objective and not time consuming method to evaluate severity in ICU Patients. However indexes measured on the first 24 hours of ICU staying are a result of severity of illness, treatment performed and time elapsed before ICU admission, and, this may be a possible source of bias when comparing different Unit results.
 ...
PMID:[Severity evaluation of ventilated patients at a respiratory intensive care unit with the APACHE II system]. 159 71

We reviewed the records of all patients in the intensive care unit (ICU) who had Pseudomonas aeruginosa pneumonia over a 2.5-year period. Of patients with P aeruginosa pneumonia, 20 of 34 survived the initial episode of pneumonia. Ten of these 20 developed recurrence. In the nonrecurrent group, nine of ten survived hospitalization, compared to only four of ten in the recurrent group. Comparing the recurrent to the nonrecurrent group, factors associated with recurrence were the APACHE 2 score (12.3 +/- 2.7 vs 8.6 +/- 4.2 [p less than 0.03]), APS score (7.0 +/- 3.5 vs 2.7 +/- 2.1 [p less than 0.01]), and chronic pulmonary disease (8/10 vs 2/10 [p less than 0.05]). The recurrent P aeruginosa group was younger (63 +/- 10 vs 74 +/- 11 years old [p less than 0.03]) and spent more time receiving mechanical ventilation (95 +/- 64 vs 26 +/- 36 days [p less than 0.01]), in the ICU (101 +/- 61 vs 33 +/- 35 days [p less than 0.01]), and in the hospital (144 +/- 77 vs 84 +/- 32 days [p less than 0.03]). Although not statistically significant, in the recurrent group, eight of ten patients had tracheostomy and seven of ten had COPD, vs three of ten and two of ten, respectively, in the nonrecurrent group. Recurrent P aeruginosa pneumonia in the ICU is associated with increased morbidity and mortality and does not appear to be related to the adequacy of antibiotic treatment. Chronic lung disease appears to predispose patients to recurrent P aeruginosa pneumonia.
 ...
PMID:Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit. 172 69

One hundred and fifteen patients with acute radiation disease of degrees I to IV affected during the accident at the Chernobyl APS were treated in a specialized hospital. The anti-infection regimen included isolation, air sterilization with ultraviolet light, intravenous administration of broad spectrum of antibiotics (gentamicin, cephalosporins and carbenicillin) and nystatin. Some cases were treated with amphotericin. Some cases were treated with amphotericin B. Out of 22 patients who died at the early periods (days 14 to 34) or at the period of agranulocytosis in 7 patients sepsis was stated. In 5 of them it was complicated by pneumonia. In 5 patients who died at the late periods (days 48 to 99) or at the period of hemopoiesis normalization infectious complications by the death moment were stated: sepsis in 3 patients and pneumonia in 2 patients. The aspect of the microbiological diagnosis and therapy efficacy is discussed.
 ...
PMID:[Combined antibiotic therapy of acute radiation disease in persons affected during the accident at the Chernobyl nuclear power station]. 281 90

We studied the diagnostic value of the detection of soluble pneumococcal antigens by counter-immunoelectrophoresis (ES) in patients with pneumonia. Pneumococcal antigens were detected in blood, urine and pleural fluid. 59 patients were distributed into 3 groups: (Group 1) - 19 patients with a non-pneumococcal, but bacteriologically-proven pneumonia, (Group 2)-32 patients with a bacteriologically confirmed pneumococcal pneumonia, (Group 3)-8 patients with a non-bacteriologically proven pneumonia, but with pneumococcal antigens. No Group 1 patients had pneumococcal antigens. In Group 2 pneumococcal antigens were present in 15 cases. The sensitivity of ES in the detection of soluble pneumococcal antigens (APS) in the blood, urine and pleural fluid during pneumococcal pneumonias was 57.5%. There was a diagnostic benefit when compared to bacteriological analysis alone of 20%. We believe that ES is a useful complementary examination to classical bacteriology.
 ...
PMID:[Contribution of the determination of soluble antigens to the diagnosis of Streptococcus pneumoniae pneumopathies]. 618 57

Whether febrile illnesses in the intensive care unit (ICU) have unique spectrum, etiologies, and outcome has not been determined in liver transplant recipients. We studied 78 consecutive febrile patients over a 4-yr period; 49% (38/78) were in the ICU and 51% (40/78) were in the non-ICU setting. Of febrile patients in the ICU, 87% (33/38) had infection and 13% had non-infectious etiology for fever. Seventy-nine percent (26/33) of the infections associated with fever in the ICU were bacterial, 9% (3/33) were viral, and 9% (3/33) were fungal in etiology. Pneumonia (30%), catheter-related bacteremia (15%), and biliary tree (9%) were the predominant sources of infections associated with fever in the ICU. Bacteremia was documented in 45% of the patients with fever in the ICU. Fifty-three percent (20/38) of the febrile episodes in the ICU occurred during the initial post-transplant stay, and 47% (18/ 38) during a subsequent readmission. Pneumonia accounted for 41% of all febrile infections during the first 7 d of ICU stay, but only 14% of those after 7 d. Febrile patients in the ICU had higher APACHE II scores (p = 0.001), higher APS scores (p = 0.0001), higher bilirubin (p = 0.001), lower cholesterol (p = 0.019), higher prothrombin time (p = 0.001), were more tachycardiac (p = 0.002), and were more likely to have abnormal blood pressure (p = 0.001) than those in the non-ICU setting. Twenty-three percent of all infections in the ICU were unaccompanied by fever and 9% were accompanied by hypothermia. Mortality at 14 d (24 versus 0%, p = 0.001) and at 30 d (34 versus 5%, p = 0.001) was significantly higher in febrile patients in the ICU, as compared to the patients in the non-ICU setting. These data have implications for diagnostic evaluation and management of critically ill febrile liver transplant recipients.
 ...
PMID:Fever in liver transplant recipients in the intensive care unit. 1061 41

Autoimmune polyendocrine syndrome type 1 (APS-1), also known as Autoimmune Polyendocrinopathy Candidiasis and Ectodermal Dysplasia (APECD) is a disorder caused by mutations in the autoimmune regulator (AIRE) gene. In some APS-1 patients, significant pulmonary disease is observed. Autoantibodies directed against the potassium channel regulatory protein (KCNRG), found in epithelial cells of terminal bronchioles, have been suggested as a marker for pulmonary disease in APS-1 patients. We report two patients with APS-1; one with and one without lung disease. Patient 1 had multiple admissions for pneumonia and respiratory insufficiency, required non-invasive ventilation, and had findings of bronchiectasis on thoracic imaging and significant lymphocytic infiltrates of the airways on lung biopsy. To verify the autoimmune cause of pulmonary symptoms APS-1 patients, both were tested in a blinded manner for the presence of autoantibodies to KCNRG in serum. We found that only Patient 1 had autoantibodies present. Additionally, Patient 1 had progressive disease despite treatment with several immunomodulating agents, including corticosteroids, azathioprine, and mycophenolate. Patient 1 had a lung biopsy performed which was consistent with B cell lymphocytic aggregates. Rituximab treatment was initiated with apparent good response. This report illustrates the practical use of KCNRG autoantibodies to identify APS-1 patients with pulmonary risk and the successful use of the monoclonal antibody, Rituximab, to treat pulmonary disease in APS-1 patients.
 ...
PMID:Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. 2190 51

BACKGROUND Due to the lack of validation for predictive scoring of stroke-associated pneumonia in both thrombolysis- and nonthrombolysis-treated ischemic stroke (IS) patients, this study aimed to evaluate 4 scoring methods in the 2 subgroups. MATERIAL AND METHODS The CerebroVascular Database Project database included data from patients with cerebral IS that were admitted in 2 hospitals from February 2016 to January 2018. A total of 138 thrombolysis-treated and 138 nonthrombolysis-treated IS patients were enrolled. Area under receiver operating characteristic curves (AUROC) were performed to examine the discrimination of the 4 scores, and Hosmer-Lemeshow test was used to evaluate the goodness of fit. RESULTS The incidence of stroke-associated pneumonia was 24.8%. The thrombolysis and nonthrombolysis subgroups were not significantly different with regard to sex, present smoking, chronic obstructive pulmonary disease history, atrial fibrillation history, blood pressure, or glucose level on admission. However, significant differences were found in National Institutes of Health Stroke Scale scores (P<0.001), Glascow Coma Scale scores (P<0.001), Oxfordshire Community Stroke Project classification (P<0.001), dysphagia (P<0.001), and white blood cell counts (P=0.039). The AUROC for the Age, Atrial fibrillation, Dysphagia, male Sex, stroke Severity, National Institutes of Health Stroke Scale; Preventive ANtibacterial THERapy in acute Ischemic Stroke; Acute Ischemic Stroke-Associated Pneumonia Score (AIS-APS); and Independence, Sex, Age, National Institutes of Health Stroke Scale scores in total population were 0.80 (0.74-0.84), 0.75 (0.69-0.80), 0.80 (0.76-0.85), and 0.76 (0.71-0.81). The goodness of fit was 0.22, 0.22, 0.27, and 0.17, respectively. The AUROC of 4 scores between subgroups were not statistically significant. CONCLUSIONS The AIS-APS had the highest AUC and goodness of fit in our population. All 4 scores can be applied regardless of whether thrombolysis has been performed on patients.
 ...
PMID:Do We Need to Distinguish Thrombolysis and Nonthrombolysis Patients When Applying Stroke-Associated Pneumonia Predicting Scores? An External Validation from a 2-Center Database. 3292 86